Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, December 8, 2015

Learn more about 3-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg

Learn more about 3-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg

Freedon to... Be Bold. Be True. Be You. It's Your Future

Watch doctors share their experiences
Watch Dr. Stuart Fox and other doctors talk about their patients’ experiences with 3-times-a-week COPAXONE®
40 mg.
Doctors have been compensated by Teva Neuroscience, Inc.

Some have specifically said they enjoy the fact that if they go away for a weekend, they don't need to take medication with them.

Injections must be at least 48 hours apart.

—Stuart Fox, MD

Watch more perspectives

Take control with a proven therapy
3-times-a-week COPAXONE® 40 mg is the #1 prescribed therapy for relapsing MS in the US1*
Proven effective in the largest pivotal trial ever conducted for COPAXONE®2
A demonstrated safety and tolerability profile in the pivotal trial, with side effects usually mild in intensity2
Full access to Teva’s Shared Solutions® network of personalized caring support

If you’re considering Teva’s COPAXONE®, making an informed therapy decision begins by having an honest discussion with your doctor. Use our Decision Brochure to talk to your doctor about Teva’s COPAXONE®.

Learn More

COPAXONE Co-pay Solutions®
Through COPAXONE Co-pay Solutions®, if eligible, your co-pay for 3-times-a-week COPAXONE® 40 mg could be lowered to $0 per month out of pocket.
Terms and conditions apply.

COPAXONE® is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Important Safety Information

Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. 

If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.

Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.

A permanent indentation under the skin (lipoatrophy or, rarely, 
necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.

The most common side effects in studies of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
or call 1‑800‑FDA‑1088.

*Based on total number of prescriptions for relapsing forms of MS (IMS Health National Prescription Audit, July 2015). All Rights Reserved by IMS.

Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply.
Terms and Conditions: COPAXONE Co-pay Solutions® is open to both new and existing patients who are residents of the US or Puerto Rico and who have commercial prescription insurance coverage for COPAXONE® 40 mg. The offer is not valid for uninsured patients or patients covered in whole or in part by Medicaid, Medicare, TRICARE, or any other federal or state government pharmaceutical assistance plan or program (regardless of whether a specific prescription is covered), or by private health benefit programs that reimburse for the entire cost of prescription drugs. Use of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or private third-party payor. This offer is void where prohibited by law, taxed, or restricted. No additional purchase is required. This offer is valid only at participating pharmacies and may be changed or discontinued at any time without notice. This program is not health insurance.

Shared Solutions
References: 1. IMS Health National Prescription Audit, July 2015. Data proprietary to IMS Health. 2. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 1/2014. Teva Neuroscience, Inc

Shared Solutions
COPAXONE® and COPAXONE CO-PAY SOLUTIONS® are registered trademarks of Teva Pharmaceutical Industries Ltd.
Shared Solutions® is a registered service mark of Teva Neuroscience, Inc.
© 2015 Teva Neuroscience, Inc. COP-43079
Teva Neuroscience, Inc., COPAXONE® Marketing, 11100 Nall Avenue, Overland Park, KS 66211

MS Views and News helps to provide information for all affected by MS
to receive MS news and information
register here

No comments: